Results 91 to 100 of about 19,810 (202)

Tenofovir alafenamide revisited.

Le infezioni in medicina, 2021
Two Tenofovir pro-drugs are available for the treatment of HIV and HBV infection. Tenofovir Alafenamide (TAF) was clinically developed as a safer alternative to the older Tenofovir Disoproxil Fumarate (TDF) as the latter was consistently found to be associated to proximal renal tubule dysfunction and decrease in bone mineral density (BMD).
openaire   +1 more source

Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide

, 2020
Background: To overcome safety limitations of tenofovir-disoproxil, EASL guidelines proposed switching chronic hepatitis B patients older than 60 years or with bone or renal disease to tenofovir-alafenamide or entecavir.
Lunghi G., Tabernero D., Soffredini R., Roade L., Loglio A., Borghi M., Esteban R., di Paolo D., Facchetti F., Lampertico P., Buti M., Riveiro-Barciela M.   +11 more
core   +1 more source

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection

, 2018
HIV treatment with tenofovir alafenamide fumarate (TAF) has decreased renal toxicity compared with tenofovir disoproxil fumarate in clinical trials. We report the case of a patient with HIV/HCV coinfection who was started on a TAF-based HIV regimen and ...
Serota, David P, Cartwright, Emily J, Franch, Harold A   +2 more
core   +1 more source

Main HCV and HIV-related efficacy outcomes.

, 2020
(A) SVR12 overall (primary endpoint) and according to race, HIV TAF regimen, HCV treatment history, and cirrhosis status. (B) HIV virologic outcome (HIV RNA ≤50 copies/mL) at Week 24 by FDA-defined snapshot algorithm.
Thai Nguyen-Cleary (4235302), Mamta K. Jain (8374734), Federico Hinestrosa (8374737), Stephanie Cox (8374758), Gregory D. Huhn (8374731), Moti Ramgopal (4559698), David M. Asmuth (8374740), Shuping Jiang (8374755), Richard H. Haubrich (8374767), David Piontkowsky (2795320), Lorenzo Rossaro (8374764), Jihad Slim (8374743), Deborah Goldstein (8374746), Moupali Das (364170), Shauna Applin (8374749), Julie H. Ryu (8374752), Bill Guyer (8374761)   +16 more
core   +1 more source

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Frontiers in Pharmacology
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang   +4 more
doaj   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Journal of Clinical Virology Plus
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity ...
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione   +6 more
doaj   +1 more source

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens - Fig 3

, 2020
Renal safety as measured by eGFRCGa(A), urine albumin to creatinine ratiob(B), urine RBP to creatinine ratiob(C), and urine beta-2-microglobulin to creatinine ratioc(D) plotted as % change from baseline over time by TAF regimen.aFor eGFRCG, measurements ...
Thai Nguyen-Cleary (4235302), Mamta K. Jain (8374734), Federico Hinestrosa (8374737), Stephanie Cox (8374758), Gregory D. Huhn (8374731), Moti Ramgopal (4559698), David M. Asmuth (8374740), Shuping Jiang (8374755), Richard H. Haubrich (8374767), David Piontkowsky (2795320), Lorenzo Rossaro (8374764), Jihad Slim (8374743), Deborah Goldstein (8374746), Moupali Das (364170), Shauna Applin (8374749), Julie H. Ryu (8374752), Bill Guyer (8374761)   +16 more
core   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: a new paradigm?

, 2018
A switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) was associated with a better renal and bone profile. Some studies reported liver toxicity due to TDF.
Celesia, B, De Socio, G, Menzaghi, B, Bonfanti, P, Salomoni, E, Cordier, L, Falasca, K, Pellicano, G. F., Maggi, P, Passerini, S, Migliorino, G, Mameli, M, Di Biagio, A, Squillace, N, Martinelli, C, Ricci, E   +15 more
core  

Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase

Вопросы вирусологии
Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF).
Ekaterina N. Ozhmegova, Anna I. Kuznetsova, Aleksey V. Lebedev, Anastasia A. Antonova, Kristina V. Kim, Yana M. Munchak, Alexander S. Tumanov, Elena V. Kazennova   +7 more
doaj   +1 more source